SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Controlling HBsAg as a Key Component of a Combination Strategy to Affect an HBV Cure- Michael Sofia, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Studies of the HBV-immune modulator AIC649 (not yet available)- Helga Rübsamen-schaeffView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Immunotherapy is coming for HCC- Spiros Hiotis, MD, PhDView Slideset
SLStephen LocarniniBSc(Hons), PhD, MBBS, FRC(Path)SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017SB 9200: A novel RIG-I agonist for chronic hepatitis B- Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)View Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Looking back to move forward: designing next-gen RNAi for best results in HBV- Bruce GivenView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017New directions towards functional cure of Chronic Hepatitis B- Lawrence Blatt, PhDView Slideset
FZFabien ZoulimMD, PhDSlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Is there a best Direct Acting Antiviral in development?- Fabien Zoulim, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Is there a best immunomodulator in development?- Ulrike ProtzerView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Is There a Best Host Acting Antiviral for HBV Cure?- Jake LiangView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017HEV Update: Diagnostics and Management- Kenneth Sherman, MD, PhDView Slideset
